EC
TCRX icon

EcoR1 Capital’s TScan Therapeutics TCRX Stock Holding History

EcoR1 Capital’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-662,833
Closed -$915K – 49
2025
Q1 		$915K Sell
662,833
-4,337,167
-87% -$9.38M 0.05% 42
2024
Q4 		$15.2M Hold
5,000,000
– – 0.57% 32
2024
Q3 		$24.9M Hold
5,000,000
– – 0.85% 29
2024
Q2 		$29.3M Hold
5,000,000
– – 0.89% 25
2024
Q1 		$39.7M Hold
5,000,000
– – 1% 23
2023
Q4 		$29.1M Hold
5,000,000
– – 0.76% 25
2023
Q3 		$12.8M Hold
5,000,000
– – 0.43% 33
2023
Q2 		$12.5M Buy
+5,000,000
New +$13.4M 0.31% 31

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

EcoR1 Capital's TCRX Position: Q2 2025 in Review

EcoR1 Capital sold out of TScan Therapeutics (TCRX) in Q2 2025, closing a stake of 662,833 shares — an estimated $915K sold.

EcoR1 Capital first reported a position in TCRX in Q2 2023 and held it in 8 quarters. The position peaked at $39.7M in Q1 2024. 81 funds tracked by Wall St. Rank hold TCRX as of Q2 2025.

  • EcoR1 Capital reported no remaining TScan Therapeutics position as of Q2 2025 after selling out during the quarter.
  • EcoR1 Capital sold 662,833 TScan Therapeutics shares in Q2 2025, an estimated $915K.
  • EcoR1 Capital first reported a position in TScan Therapeutics in Q2 2023 and held it in 8 quarters.
  • EcoR1 Capital's TScan Therapeutics position peaked at $39.7M in Q1 2024.
  • 81 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2025.

Based on EcoR1 Capital's 13F filing for Q2 2025, filed 14 Aug 2025.